截至2026年9月30日止九个月，华润医药通过其非全资附属公司天士力医药实现营收60.74亿元（去年同期63.11亿元），同比下降3.76%；净利润10.87亿元（去年同期9.93亿元），同比增长9.52%。
天士力医药报告期内现金及现金等价物净减少4.78亿元，期末现金及现金等价物余额为9.37亿元。同期末，总资产达150.65亿元，总负债为20.22亿元，所有者权益130.43亿元。上述财务数据基于中国公认会计准则编制，仅代表天士力医药经营业绩并不全面反映华润医药整体财务状况。
截至2026年9月30日止九个月，华润医药通过其非全资附属公司天士力医药实现营收60.74亿元（去年同期63.11亿元），同比下降3.76%；净利润10.87亿元（去年同期9.93亿元），同比增长9.52%。
天士力医药报告期内现金及现金等价物净减少4.78亿元，期末现金及现金等价物余额为9.37亿元。同期末，总资产达150.65亿元，总负债为20.22亿元，所有者权益130.43亿元。上述财务数据基于中国公认会计准则编制，仅代表天士力医药经营业绩并不全面反映华润医药整体财务状况。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.